Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma

Internal Medicine Journal

Volumn 42, Issue 10, 2012, Pages 1113-1119

  Keane, C ^a,b   Nourse, J P ^b   Crooks, P ^b   Nguyen Van, D ^b   Mutsando, H ^a   Mollee, P ^a   Lea, R A ^c   Gandhi, M K ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Diffuse large B cell lymphoma; Genetic polymorphisms; Late onset neutropenia; Rituximab

Indexed keywords

CD16 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC GAMMA RECEPTOR 3A; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EVENT FREE SURVIVAL; FEMALE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENOTYPE; HOMOZYGOSITY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HOMOZYGOTE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEUTROPENIA; PREDNISONE; PROSPECTIVE STUDIES; RECEPTORS, IGG; TIME FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 84867473636     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02587.x     Document Type: Article

References (36)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R etal. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. de Haij S, Jansen JHM, Boross P, Beurskens FJ, Bakema JE, Bos DL etal. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70: 3209-3217.
3. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM etal. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659-1669.
4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446.
5. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y etal. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008; 112: 1205-1213.
6. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E etal. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587.
7. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T etal. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383-3389.
8. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S etal. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
9. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM etal. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 2003; 101: 1071-1079.
10. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE etal. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-3288.
11. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
12. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G etal. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
13. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M etal. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-3718.
14. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH etal. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108: 2720-2725.
15. Mitrovic Z, Aurer I, Radman I, Ajdukovic R, Sertic J, Labar B. FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 2007; 92: 998-999.
16. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC etal. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85: 810-812.
17. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28: 279-284.
18. Hincks I, Woodcock BE, Thachil J. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 2011; 153: 411-413.
19. Racila E, Racila DM, Ritchie JM, Taylor C, Dahle C, Weiner GJ. The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 2006; 58: 1-8.
20. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ etal. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14: 6697-6703.
21. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ etal. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
22. Racila DM, Sontheimer CJ, Sheffield A, Wisnieski JJ, Racila E, Sontheimer RD. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 2003; 12: 124-132.
23. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C etal. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
24. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T etal. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106: 795-802.
25. Kim M, Lee JK, Hong YJ, Hong SI, Kang HJ, Chang YH. [Late-onset neutropenia following rituximab therapy as a treatment of diffuse large B-cell lymphoma: a single institution study]. Korean J Lab Med 2010; 30: 575-579.
26. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-918.
27. Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J etal. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008; 25: 374-379.
28. Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009; 84: 414-417.
29. Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A etal. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18: 364-369.
30. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26: 597-600.
31. Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C etal. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 2000; 18: 325-331.
32. Terrier B, Ittah M, Tourneur L, Louache F, Soumelis V, Lavie F etal. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007; 92: e20-23.
33. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S etal. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007; 110: 2561-2564.
34. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
35. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28: 279-284.
36. Weng WK, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 2009; 50: 1494-1500.